Prothena Corporation plc

LSE:0Y3M Stock Report

Market Cap: US$382.2m

Prothena Valuation

Is 0Y3M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0Y3M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$61.63
Fair Value
87.8% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: 0Y3M ($7.5) is trading below our estimate of fair value ($61.63)

Significantly Below Fair Value: 0Y3M is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0Y3M?

Key metric: As 0Y3M is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0Y3M. This is calculated by dividing 0Y3M's market cap by their current revenue.
What is 0Y3M's PS Ratio?
PS Ratio2.8x
SalesUS$137.94m
Market CapUS$382.17m

Price to Sales Ratio vs Peers

How does 0Y3M's PS Ratio compare to its peers?

The above table shows the PS ratio for 0Y3M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
OXB Oxford Biomedica
2.4x16.5%UK£314.3m
BVXP Bioventix
10.9xn/aUK£148.9m
GNS Genus
2.1x3.9%UK£1.4b
AVCT Avacta Group
5.6x-27.0%UK£125.6m
0Y3M Prothena
2.9x41.4%US$382.2m

Price-To-Sales vs Peers: 0Y3M is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does 0Y3M's PS Ratio compare vs other companies in the GB Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.7.2x8.6%
0Y3M Prothena
 2.9x41.4%US$382.17m
GNS Genus
2.1x3.9%US$1.85b
OXB Oxford Biomedica
2.4x16.5%US$418.36m
0Y3M 2.8xIndustry Avg. 7.2xNo. of Companies8PS020406080100+
9 CompaniesEstimated GrowthMarket Cap
Industry Avg.7.2x29.0%
0Y3M Prothena
 2.9x26.3%US$382.17m
No more companies

Price-To-Sales vs Industry: 0Y3M is good value based on its Price-To-Sales Ratio (2.9x) compared to the European Biotechs industry average (7.2x).

Price to Sales Ratio vs Fair Ratio

What is 0Y3M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0Y3M PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.8x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: 0Y3M is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0Y3M forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.50
US$49.25
+556.8%
61.2%US$110.00US$18.00n/a8
May ’26US$8.76
US$51.75
+490.8%
56.1%US$110.00US$20.00n/a8
Apr ’26US$11.93
US$51.75
+333.8%
56.1%US$110.00US$20.00n/a8
Mar ’26US$15.60
US$51.75
+231.7%
56.1%US$110.00US$20.00n/a8
Feb ’26US$14.54
US$49.75
+242.2%
49.2%US$94.00US$22.00n/a8
Jan ’26US$13.15
US$49.75
+278.5%
49.2%US$94.00US$22.00n/a8
Dec ’25US$16.22
US$60.43
+272.6%
43.4%US$94.00US$24.00n/a7
Nov ’25US$16.62
US$61.14
+267.9%
41.4%US$94.00US$24.00n/a7
Oct ’25US$16.67
US$55.88
+235.1%
43.5%US$94.00US$24.00n/a8
Sep ’25US$22.15
US$62.50
+182.2%
37.7%US$94.00US$24.00n/a8
Aug ’25US$22.42
US$64.75
+188.8%
36.1%US$94.00US$28.00n/a8
Jul ’25US$20.53
US$64.75
+215.4%
36.1%US$94.00US$28.00n/a8
Jun ’25US$21.19
US$64.75
+205.6%
36.1%US$94.00US$28.00n/a8
May ’25US$21.99
US$66.09
+200.5%
32.3%US$94.00US$34.00US$8.7610
Apr ’25US$24.91
US$65.72
+163.8%
31.0%US$94.00US$34.00US$11.9311
Mar ’25US$28.30
US$66.08
+133.5%
30.0%US$94.00US$35.00US$15.6011
Feb ’25US$27.93
US$73.24
+162.2%
29.7%US$100.00US$36.00US$14.5412
Jan ’25US$36.58
US$81.66
+123.2%
30.9%US$129.00US$43.00US$13.1512
Dec ’24US$33.90
US$83.45
+146.2%
30.7%US$129.00US$43.00US$16.2211
Nov ’24US$35.67
US$87.89
+146.4%
26.2%US$129.00US$52.90US$16.6210
Oct ’24n/a
US$93.44
0%
21.1%US$129.00US$60.00US$16.679
Sep ’24US$54.76
US$93.44
+70.7%
21.1%US$129.00US$60.00US$22.159
Aug ’24US$62.80
US$93.33
+48.6%
21.2%US$129.00US$60.00US$22.429
Jul ’24US$68.14
US$93.00
+36.5%
20.2%US$129.00US$60.00US$20.5310
Jun ’24US$64.69
US$92.10
+42.4%
18.7%US$120.00US$60.00US$21.1910
May ’24n/a
US$85.60
0%
20.0%US$120.00US$55.00US$21.9910
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
US$49.71
Fair Value
84.9% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/09 20:38
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prothena Corporation plc is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Tazeen AhmadBofA Global Research
null nullBTIG